Bundibugyo Ebola

Uganda completed the monitoring period without detecting further transmission, providing an additional safeguard that no transmission chains linked to the imported case had been missed.

The ICG will allocate 20,000 doses to a Phase 3 clinical trial designed to assess whether Ervebo can protect people against Bundibugyo virus.

Following a review of the latest epidemiological data, the ECG noted that the DRC had recorded 4,449 confirmed Ebola cases and 2,061 confirmed deaths, representing a case-fatality rate of 46.3%.

The Phase 1 study forms part of an expanded collaboration between Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI).

The initiative comes as scientists intensify efforts to address a major Bundibugyo ebolavirus outbreak, with cases rising rapidly in the Democratic Republic of the Congo (DRC).

Throughout the 42-day period, health authorities maintained enhanced nationwide surveillance and found no evidence of further transmission.

The experimental vaccine was developed by scientists at the University of Oxford using the same vaccine technology employed in the Oxford-AstraZeneca COVID-19 vaccine.

The country has also discharged its last Ebola patient and entered the 42-day countdown required to declare the outbreak over.

The BD-Ebov trial, which is being conducted in Oxford, will evaluate the safety, tolerability and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged between 18 and 55 years.

The EBO-PEP platform trial, which has been under development since 2024, will evaluate several medicines as post-exposure prophylaxis for people who have had high-risk contact with filoviruses, the virus family that includes Bundibugyo Ebola.